MabVax Therapeutics Raises $1.3M In PIPE

San Diego-based biotechnology developer MabVax Therapeutics, which is publicly traded on the Nasdaq as MBVX, said today that it has launched a registered direct offering which will provide the company of $1,312,500. The Series J Convertible Preferred Stock comes from un-nnamed investors, and will go towards working capital and general corporate purposes. The new funding comes as MabVax looks to find a buyer for the company.